-
Renmark Virtual Non-Deal Roadshow: NASDAQ - INM (ID 2859)
- Overview 1 Intro 0:00:00 2 Forward Looking Statements 0:00:39 3 Executive Summary & Highlights 0:00:52 4 Pharmaceutical Pipeline 0:01:58
- Alzheimer's Disease 5 Major Medical & Societal Burden 0:02:13 6 Neuroinflammation Response 0:02:38 7 Microglia and Astrocytes 0:03:29 8 Role of CB1/CB2 Receptors 0:04:18
- INM-901 9 Mechanism of Action 0:04:51 10 Proof of Concept in Alzheimer's 0:05:30 11 Positive Trends Across all Parameters 0:07:04 12 Neuroinflammatory Modulation 0:09:59 13 Summary 0:10:34
- AMD 14 Macular Degeneration 0:12:10 15 Occurs When Macula is Damaged 0:12:44 16 Improved Retinal Pigment 0:13:52 17 INM-089: A Differentiated Approach 0:14:49 18 INM-755 Cannabinol (CBN) Cream 0:15:18
- Corporate 19 Experienced Team 0:18:11 20 Distinguished Board of Directors 0:18:33 21 Financial Snapshot 0:18:57
- Summary 22 Key Value Drivers 2026/2027 0:20:11 23 Contact Info 0:22:04
- Question Period 24 Questions 0:22:12 25 INM-901 Phase 1? 0:22:17 26 Clinical Trial Execution? 0:23:03 27 Phase 1 Enrollment? 0:23:59 28 Preclinical Data? 0:25:09 29 Orphan Drug Designation? 0:27:32 30 Partnership Level? 0:28:38 31 ALS & MS? 0:29:33 32 INM-089 Benefits? 0:30:49 33 INM-089 Monotherapy? 0:31:43 34 IP Coverage? 0:32:47
- Final Remarks 35 Outro 0:33:37
0:00:00 | 0:34:40
Renmark Virtual Non-Deal Roadshow: NASDAQ - INM (ID 2859)
Subscribe
Open Interactive SlidelistSlidelist
